NYSE:ELANPharmaceuticals
Is Elanco (ELAN) Quietly Redefining Its Innovation Edge With Longer‑Lasting Canine Allergy Antibodies?
Elanco Animal Health has begun a phased U.S. launch of Befrena (tirnovetmab), an anti‑IL‑31 monoclonal antibody injection for canine allergic and atopic dermatitis, offering 6 to 8 weeks of itch relief and rapid onset in Early Experience Program clinics.
The product expands Elanco’s dermatology and monoclonal antibody lineup, making it the only pet health company with two USDA‑approved mAb therapies and broadening its presence in pet allergy care.
We’ll now examine how Befrena’s...